Abstract
Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Current Drug Safety
Title: Proton Pump Inhibitor Therapy and Osteoporosis
Volume: 3 Issue: 3
Author(s): Yu-Xiao Yang
Affiliation:
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Abstract: Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Export Options
About this article
Cite this article as:
Yang Yu-Xiao, Proton Pump Inhibitor Therapy and Osteoporosis, Current Drug Safety 2008; 3(3) . https://dx.doi.org/10.2174/157488608785699414
DOI https://dx.doi.org/10.2174/157488608785699414 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Safety of One-week, First-line, Standard Triple Therapy for Helicobacter pylori Eradication in a Japanese Population
Current Drug Safety Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Current Pharmaceutical Design Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Therapeutic Potential of Cholesteryl O-acyl α-glucoside Found in Helicobacter pylori
Current Medicinal Chemistry Mucosal Immune Regulation and Vaccines for Helicobacter-associated Gastritis
Current Chemical Biology Bioactivity and Enzyme Inhibition Properties of Stevia rebaudiana
Current Enzyme Inhibition Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy
Current Pharmaceutical Biotechnology Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Editorial [Hot topic: Models and Evolution of Inflammatory Activities (Executive Editor: Giuseppe Scapigliati)]
Current Pharmaceutical Design The Use of N-Acetyl Cysteine <i>Versus</i> Chromium Picolinate as an Adjuvant to Clomiphene Citrate and Metformin in PCOS Women to Improve Ovulation Induction and Insulin Resistance: A Pilot Randomized Controlled Trial
Current Women`s Health Reviews